生育酚结合蛋白基因重组腺相关病毒的制备及抗癌作用  

作　　者：李小娟[1] 王喻[2] 朱宝益[2] 叶春伟[2] 杨钦泰[3] 黄振华[4] 洪莹芬[5] 文娅[5] 温星桥[2] 

机构地区：[1]中山大学附属第三医院预防保健科,广州510630 [2]中山大学附属第三医院泌尿外科,广州510630 [3]中山大学附属第三医院耳鼻咽喉-头颈外科,广州510630 [4]中山大学中山医学院药理学系 [5]中山大学中山医学院

出　　处：《中华实验外科杂志》2011年第8期1363-1366,共4页Chinese Journal of Experimental Surgery

基　　金：基金项目：国家自然科学基金资助项目（81072115、30901768）;高校基本科研业务费中山大学青年教师培育项目（10ykpy06）

摘　　要：目的制备生育酚结合蛋白（TAP）重组腺相关病毒，并探讨其对前列腺癌生长的作用。方法构建重组腺相关病毒质粒pSNAV-TAP-EGFP，酶切、聚合酶链反应（PCR）、测序。225cm2细胞培养瓶中，接种293T细胞，以重组质粒转染。扩增、纯化病毒，并转染DU-145细胞，噻唑蓝（MTT）比色法观察第2、4、6天的细胞增殖。结果成功构建pSNAV—TAP—EGFP质粒，并制备滴度6．4×10^11vg／ml、纯度95％的rAAV2-TAP。该病毒转染DU-145细胞后TAP表达量明显上升。转染后第4天，TAP转染组的细胞吸光度（A值）0．546±0．072，对照组以及空载体转染组的A值分别为0．673±0．015、0．638±0．051，生长明显受到抑制（P〈0．05）。至第6天各组细胞生长差异更显著。结论成功制备高滴度的rAAV—TAP—EGFP病毒，并可抑制前列腺癌细胞的生长。Objective To produce recombinant rAAV2 virus carrying α-tocopherol associated protein (TAP) and to observe its effect on prostate cancer cells. Methods The pSNAV-TAP-EGFP plasmid was constructed and digested with restriction enzyme. Polymerase chain reaction (PCR), and sequence analysis were performed to identify the correct recombinant clones. The plasmid was transfected into 293T cells to produce virus. The virus was amplified and purified. DU-145 cells were infected by rAAV-TAPEGFP. Cell growth was detected by MTT assay. Results The pSNAV-TAP-EGFP was constructed successfully. The titer of rAAV2-TAP-virus was 6. 4 × 1011 vg/ml and the purity was 95%. The rAAV-TAP-EGFP was infected into the DU-145 cells with high efficiency. The expression of TAP was increased significantly by real-time PCR. MTT assay showed differences at the 4th day. The cellular absorbance value in the TAP transfection group, control group and empty vector transfection group was 0. 546 +0. 072, O. 673 +0. 015,and 0. 638 + 0. 051 (P ＜ 0. 05 ). The differences became more significant after 6 days. Conclusion High tier recombinant adeno-associated virus rAAV2-TAP-EGFP was obtained, which was able to inhibit the proliferation of prostate cancer cells.

关 键 词：生育酚结合蛋白 重组腺相关病毒 前列腺癌 增殖 

分 类 号：R737[医药卫生—肿瘤]